Patent ID: 9150638
Filing Date: 2015-10-06
Classification: A61K,A61P,C07K

Abstract:
1. A method of treating fibroproliferative interstitial lung disease, comprising administering to an individual a pharmaceutically effective amount of a non-endogenous inhibitor of the cellular activity of FXII/FXIIa, wherein the non-endogenous inhibitor of the cellular activity of FXII/FXIIa is selected from the group consisting of: (i) wild type Infestin-4 polypeptide sequence (SEQ ID NO: 33), or a variant thereof, wherein the variant comprises (ii) SPINK-1 (SEQ ID NO:29), which is mutated to include the N-terminal amino acids 2-13 of the wild type Infestin-4 sequence, or a variant of said mutated SPINK-1, wherein the variant comprises (iii) an antibody capable ofbinding to said FXII/FXIIa.